UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 113

Sortiert nach

Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy

Clinical cancer research, 2013-12, Vol.19 (24), p.6943-6956

2013

Volltextzugriff (PDF)

Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy

The Journal of clinical investigation, 2020-01, Vol.130 (1), p.258-271

2020

Volltextzugriff (PDF)

Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma

Haematologica (Roma), 2017-07, Vol.102 (7), p.1247

2017

Volltextzugriff (PDF)

Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft

Molecular cancer therapeutics, 2011-10, Vol.10 (10), p.1949-1958

2011

Volltextzugriff (PDF)

Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System

Cell reports (Cambridge), 2017-10, Vol.21 (5), p.1386-1398

2017

Volltextzugriff (PDF)

AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

Clinical cancer research, 2007-06, Vol.13 (12), p.3682-3688

2007

Volltextzugriff (PDF)

Discovery, Synthesis, and in Vivo Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase

Journal of medicinal chemistry, 2007-05, Vol.50 (9), p.2213-2224

2007

Volltextzugriff (PDF)

The Clinical Development of Molecularly Targeted Agents in Combination With Radiation Therapy: A Pharmaceutical Perspective

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (4), p.e447-e454

2012

Volltextzugriff (PDF)

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis

Cancer research (Chicago, Ill.), 2008-06, Vol.68 (12), p.4754-4762

2008

Volltextzugriff (PDF)

Mechanisms that influence tumour response to VEGF-pathway inhibitors

Biochemical Society transactions, 2014-12, Vol.42 (6), p.1601

2014

Volltextzugriff (PDF)

Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy

Clinical cancer research, 2008-05, Vol.14 (10), p.3124-3131

2008

Volltextzugriff (PDF)

DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models

Molecular cancer therapeutics, 2021-09, Vol.20 (9), p.1663-1671

2021

Volltextzugriff (PDF)

The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts

Clinical cancer research, 2009-11, Vol.15 (21), p.6619-6629

2009

Volltextzugriff (PDF)

Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy

Journal of medicinal chemistry, 2023-04, Vol.66 (7), p.4491-4502

2023

Volltextzugriff (PDF)

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK‑2 Selectivity of 6‑Substituted 2‑Arylaminopurines

Journal of medicinal chemistry, 2017-03, Vol.60 (5), p.1746-1767

2017

Volltextzugriff (PDF)

Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts

Molecular cancer therapeutics, 2007-08, Vol.6 (8), p.2198-2208

2007

Volltextzugriff (PDF)

A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer

Clinical cancer research, 2023-04, Vol.29 (8), p.1429-1439

2023

Volltextzugriff (PDF)

Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit

Molecular cancer therapeutics, 2007-02, Vol.6 (2), p.599-606

2007

Volltextzugriff (PDF)

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction

Journal of medicinal chemistry, 2021-04, Vol.64 (7), p.4071-4088

2021

Volltextzugriff (PDF)

Targeting Cytotoxic Agents through EGFR-Mediated Covalent Binding and Release

Journal of medicinal chemistry, 2023-09, Vol.66 (17), p.12324-12341

2023

Volltextzugriff (PDF)

Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices

Scientific reports, 2015-12, Vol.5 (1), p.17187-17187, Article 17187

2015

Volltextzugriff (PDF)

Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel

Molecular cancer therapeutics, 2015-01, Vol.14 (1), p.48-58

2015

Volltextzugriff (PDF)

Fragment expansion with NUDELs - poised DNA-encoded libraries

Chemical science (Cambridge), 2023-08, Vol.14 (31), p.8288-8294

2023

Volltextzugriff (PDF)

Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib

Scientific reports, 2017-09, Vol.7 (1), p.12020-11, Article 12020

2017

Volltextzugriff (PDF)

1 – 25 von 113

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(104)

Publikationsform

Artikel
(111)
Buchkapitel
(2)

Sprache

Englisch
(113)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

Science & Technology
(78)
Life Sciences & Biomedicine
(70)
Humans
(63)
Animals
(42)
Mice
(37)
Oncology
(31)
Cell Line, Tumor
(25)
Biological And Medical Sciences
(24)
Female
(21)
Medical Sciences
(20)
Mice, Nude
(20)
Xenograft Model Antitumor Assays
(19)
Male
(18)
Pharmacology & Pharmacy
(18)
Antineoplastic Agents
(16)
Antineoplastic Agents - Pharmacology
(16)
Pharmacology. Drug Treatments
(16)
Quinazolines - Pharmacology
(15)
Tumors
(14)
Chemistry
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy

Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy

Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma

Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft

Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System

AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

Discovery, Synthesis, and in Vivo Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase

The Clinical Development of Molecularly Targeted Agents in Combination With Radiation Therapy: A Pharmaceutical Perspective

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis

Mechanisms that influence tumour response to VEGF-pathway inhibitors

Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy

DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models

The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts

Clinical development of new drug-radiotherapy combinations

Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK‑2 Selectivity of 6‑Substituted 2‑Arylaminopurines

Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts

A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer

Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction

Targeting Cytotoxic Agents through EGFR-Mediated Covalent Binding and Release

Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices

Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel

Fragment expansion with NUDELs - poised DNA-encoded libraries

Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib

Suchergebnisse filtern